GLP-1 medications work during perimenopause, and there is no evidence that falling estrogen makes them stop working. What changes is the context you are using them in. The menopause transition shifts your body composition toward more fat and less muscle even in years when the scale barely moves, so protecting muscle stops being optional. The honest limitation is that the large semaglutide and tirzepatide trials did not report results by menopause stage. Much of what you read about GLP-1s “for perimenopause” is reasonable extrapolation rather than direct trial evidence, and you deserve to know which is which.

What perimenopause actually does to your body

The most useful data here comes from research that followed the same women through the transition rather than comparing younger women to older ones. It found something that contradicts the usual story. Weight climbed steadily through the premenopausal years and did not accelerate when the transition began. Body composition did. The rate of fat gain roughly doubled at the start of the transition, from about 1.0 percent to about 1.7 percent per year, while lean mass flipped from a small annual gain to an annual loss (Greendale and colleagues, 2019).

Read that twice, because it reframes the problem. If you feel thicker through the middle and weaker than five years ago while the scale has barely moved, you are not imagining it. Separate work found that fat redistributes toward the abdomen across the transition and that daily energy expenditure falls (Lovejoy and colleagues, 2008).

The practical conclusion is that the scale is a poor instrument for this decade of life. Waist measurement, strength, and how your clothes fit tell you more.

Muscle is the thing to protect

Roughly 20 to 40 percent of the weight lost on a GLP-1 receptor agonist is lean mass rather than fat. That sounds alarming until you see the comparison: the same review notes this is similar to very low calorie diets and to bariatric surgery, that the weight lost is mostly fat, and that measures of physical function generally hold up (review of muscle health with incretin therapies). GLP-1s are not uniquely bad for muscle.

The concern in perimenopause is arithmetic, not pharmacology. You are asking a medication to take weight off during the exact window when your body is already giving up lean mass on its own. Those two things stack.

That review recommends 1 to 1.5 grams of protein per kilogram of body weight per day, with the higher end for older adults, spread across meals rather than loaded into dinner. It also states plainly that exercise training remains one of the most effective strategies for limiting loss of lean mass and strength, which in practice means progressive resistance training two or three times a week, not just walking.

Here is the trap. These medications work by suppressing appetite, so the failure mode is not overeating. It is quietly undereating protein for months while the scale rewards you for it.

Hormone therapy alongside a GLP-1

There is an early signal here, and it deserves honest framing. At the Endocrine Society’s 2025 meeting, Mayo Clinic researchers presented a retrospective review of 120 postmenopausal women taking tirzepatide. Those also using menopause hormone therapy lost about 17 percent of body weight compared with about 14 percent for tirzepatide alone, and 45 percent of them reached at least 20 percent loss compared with 18 percent (Endocrine Society, 2025).

Now the caveats, which matter as much as the numbers. This was a retrospective look at existing records, not a randomized trial, so it cannot establish cause. It involved 120 women, it was presented as a conference abstract rather than published after peer review, and those women were postmenopausal, not perimenopausal.

None of that makes it worthless. It does mean it is not a reason to start hormone therapy in order to lose weight. The Menopause Society’s hormone therapy position statement lists the indications as vasomotor symptoms, the genitourinary syndrome of menopause, and prevention of bone loss and fracture (2022 position statement). Weight loss is not among them. If you have hot flashes, night sweats, broken sleep or vaginal symptoms, hormone therapy is worth discussing on its own merits. If weight is your only goal, it is the wrong tool.

Two things specific to this stage

You can still get pregnant. Perimenopause means unpredictable ovulation, not absent ovulation, and this gets overlooked constantly. The prescribing information for semaglutide states that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and directs that the medication be discontinued when a pregnancy is recognized (FDA label). If pregnancy is possible for you, contraception belongs in the plan, and a GLP-1 should be stopped well before a planned pregnancy.

Do not write off abnormal bleeding. Cycles become erratic in perimenopause, which makes it easy to dismiss everything as normal. But bleeding between periods, bleeding heavy enough to soak through protection hourly, or any bleeding at all after twelve months without a period needs evaluation. Do not attribute it to your hormones or to a new medication without someone looking.

Who should not take one, and when to call

Semaglutide carries a boxed warning regarding thyroid C-cell tumors observed in rodents, with the relevance to humans not established. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in anyone who has had a serious hypersensitivity reaction to it.

Seek medical care rather than waiting if you have:

Severe, persistent abdominal pain, particularly if it radiates to your back
Persistent vomiting, or an inability to keep fluids down
Pain in the upper right abdomen, or yellowing of the skin or eyes
Swelling of the face, lips or tongue, or difficulty breathing

How we work through this

At MetaHealth we treat perimenopause and weight as one clinical picture rather than two separate appointments. That means baseline labs before anything is prescribed, tracking body composition and waist rather than the scale alone, a protein target and a resistance training plan set at the start rather than added after muscle is already lost, and an honest conversation about whether your symptoms point toward hormone evaluation, weight treatment, or both. More on our approach on our medical weight loss page. We see patients in Deerfield Beach and by telehealth across Florida, in English, Portuguese and Spanish.

Medically reviewed by Krishna Borges, MSN, APRN, FNP-C. This article is for general education and is not a substitute for individual medical advice.